ALNY catalyst calendar

ALNYLAM PHARMACEUTICALS, INC.

Upcoming catalysts
20
Cash runway
Cash generating
Cash & investments
$3308M
Phase 3 programs
15

ALNYLAM PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 15, 2026, a projected date rather than a confirmed one. There are 20 upcoming events on record.

ALNYLAM PHARMACEUTICALS, INC. generates cash from operations, so a burn-based runway figure does not apply.

Across 54 concluded trials, 80% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 est. Next quarterly earnings (projected) Earnings —
December 29, 2026 A Study to Evaluate ALN-4285 in Adult Healthy Volunteers Trial Milestone Phase 1
April 28, 2027 A Study to Evaluate ALN-2232 in Participants With Obesity Trial Milestone Phase 1/Phase 2
May 28, 2027 A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus Trial Milestone Phase 2
June 30, 2027 HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB Trial Milestone Phase 2
July 31, 2027 A Study to Evaluate ALN-4915 in Adult Healthy Volunteers Trial Milestone Phase 1
August 9, 2027 A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy Trial Milestone Phase 2
August 31, 2027 A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM Trial Milestone Phase 1/Phase 2
September 30, 2027 A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma Trial Milestone Phase 1
December 14, 2027 A Study to Evaluate ALN-6222 in Participants With Obesity Trial Milestone Phase 1
December 27, 2027 TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Trial Milestone Phase 3
January 5, 2028 A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Trial Milestone Phase 1/Phase 2
March 31, 2028 A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Trial Milestone Phase 3
April 1, 2028 A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran Trial Milestone Phase 2
July 5, 2028 A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease Trial Milestone Phase 1
April 20, 2029 A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD Trial Milestone Phase 1
March 6, 2030 A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease Trial Milestone Phase 1
May 18, 2030 A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Trial Milestone Phase 2
May 28, 2030 TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Trial Milestone Phase 3
September 23, 2030 Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease Trial Milestone Phase 3

Track ALNY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ALNY in the tracker

Recent history

DateEventTypePhase
July 30, 2026 Quarterly results filed (8-K) Earnings —
May 27, 2026 8-K filed: Leadership change Corporate —
April 30, 2026 Quarterly results filed (8-K) Earnings —
March 4, 2026 8-K filed: Leadership change Corporate —
February 12, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 11, 2025 8-K filed: Other event Filing —
December 3, 2025 8-K filed: Leadership change Corporate —
October 30, 2025 Quarterly results filed (8-K) Earnings —
October 3, 2025 8-K filed: Material agreement Corporate —
September 30, 2025 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects Trial Milestone Phase 1
September 12, 2025 8-K filed: Material agreement, Other event Corporate —
September 10, 2025 8-K filed: Other event Filing —
September 8, 2025 A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers Trial Milestone Phase 1
July 31, 2025 Quarterly results filed (8-K) Earnings —
July 17, 2025 A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension Trial Milestone Phase 1/Phase 2
June 19, 2025 Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) Trial Milestone Phase 2
June 18, 2025 8-K filed: Leadership change Corporate —
April 3, 2025 A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM Trial Milestone Phase 1/Phase 2
May 8, 2024 HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Trial Milestone Phase 3
December 11, 2023 Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) Trial Milestone Phase 2
April 4, 2023 A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension Trial Milestone Phase 2
February 7, 2023 An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 Trial Milestone Phase 2
January 25, 2023 A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout Trial Milestone Phase 1/Phase 2
January 6, 2023 A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) Trial Milestone Phase 1
November 23, 2022 The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) Trial Milestone Phase 3
November 1, 2022 A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels Trial Milestone Phase 2
June 20, 2022 APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) Trial Milestone Phase 3
April 20, 2022 A Study to Evaluate ALN-AGT01 in Patients With Hypertension Trial Milestone Phase 1
March 17, 2022 A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.